CA2070263A1 - Hepatocyte-growth agent - Google Patents
Hepatocyte-growth agentInfo
- Publication number
- CA2070263A1 CA2070263A1 CA002070263A CA2070263A CA2070263A1 CA 2070263 A1 CA2070263 A1 CA 2070263A1 CA 002070263 A CA002070263 A CA 002070263A CA 2070263 A CA2070263 A CA 2070263A CA 2070263 A1 CA2070263 A1 CA 2070263A1
- Authority
- CA
- Canada
- Prior art keywords
- hhgf
- hepatocyte
- heparin
- derivative
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Abstract
Abstract:
Disclosed is a hepatocyte-growth agent which comprises a polysaccharide or a derivative thereof, heparin, heparan sulfate, chondroitin sulfate and dextran sulfate and a hepatocyte-growth factor (hHGF) obtained by purification of plasma or recombination, by which activity of the hHGF is strengthened, and an hHGF molecule is stabilized.
Disclosed is a hepatocyte-growth agent which comprises a polysaccharide or a derivative thereof, heparin, heparan sulfate, chondroitin sulfate and dextran sulfate and a hepatocyte-growth factor (hHGF) obtained by purification of plasma or recombination, by which activity of the hHGF is strengthened, and an hHGF molecule is stabilized.
Description
TOCYTE GRQW~H~_A~ENT
~Ç~Q~ OF THE INVENTIQN
This invention relates to a hepatocyte-growth agent which promotes growth of hepatocyte, more specifically to a hepatocyte-growth agent which comprises a polysaccharide or a derivative thereof and a hepatocyte-growth factor, in which said hepatocyte-growth factor is stabilized and further, its growth activity is heightened.
In recent years, a proteinic factor derived from human, : ` which can promote growth of hepatocyte, namely, a human hepatocyte-growth factor (hereinafter sometimes abbreviated to as "hHGF") has been found in plasma of patients with fulminant hepatic failure (Japanese Provisional Patent Pub-lication No. 22526/1988). Further, there have been propos-ed an amino acid sequence and a gene (cDNA) sequence which codes hHGF protein (Japanese Provisional Patent Publication No. 72883/1991), and a method for producing hHGF protein using this cDNA and a transformant thereof (Japanese Pro-visional Paten~ Publication No. 285693/1991). It has been recognized that such an hHGF has mitogenic acti~ity for hepatocytes in vitro. In order to clarify a mechanism of growth hepatocyte by an hHGF existing in nature or a recom-- 2 - 2~
binant hHGF, the present inventors have studied binding systems of these hHGFs to hepatocyte, and consequently found that most of the hHGFs bound to hepatocyte is washed away with a buffer solution containing a polysaccharide such as glycosaminoglycan and heparin, or a derivative thereof. From the result, it was estimated that a poly-saccharide or a derivative thereof irhibits the binding of hHGF to hepatocyte, uptake of the same to hepatocyte or metabolization process thereof, all of which are considered to be indispensable to induce a hepatocyte-growth activity of the hHGF, and thus, has an action of inhibiting activity of the hHGF.
SUMMARY OF THE INVENTION
The present inventors have further studied influences of a polysaccharide or a derivative thereof exerting on a hepatocyte-growth activity of the hHGF. Namely, they have measured various influences on hepatocyte-growth activities (1) when a polysaccharide or a derivative thereof and the hHGF are mixed and added, (2) when a polysaccharide or a derivative thereof is added and then the hHGF is added, and (3) when the hHGF is added and then a polysaccharide or a derivative thereof is added to hepatocyte prepared by the Seglen's method (Methods in cellbiology, vol. 13, p. 29, Academic Press, New York (1976)).
As a result, it was interestingly found for the first time, which were different from the results estimated in the prior art techniques, that an ability of promoting growth of hepatocyte possessed by the hHGF is extremely strength-ened when a polysaccharide or a derivative thereof and the hHGF are mixed and added, and when a polysaccharide or a derivative thereof is added and then the hHGF is added, and additionally, degradation of the hHGF existing in a medium supernatant is suppressed by adding a polysaccharide or a - 3 ~ 3 derivative thereof to a system of measuring growth of hepatocyte by the hHGF, namely, an hHGF molecule is stabi-lized to accomplish the present invention.
That is, a gist of the present invention resides in a hepatocyte-growth agent which comprises a polysaccharide or a derivative thereof and a hepatocyte-growth factor.
~RI~F ~ESCRIPTIO~ OF THF ~R~WING
Fig. 1 is a diagram showing a relation between a heparin concentration and hHGF activity when hHGF activity is heightened by adding heparin.
Fig. 2 is a diagram showing a relation between an hHGF
concentration and hHGF activity when hHGF activity is heightened by adding a predetermined amount of heparin.
Fig. 3 is a diagram showing inhibition of a labeled hHGF
degradation when a predetermined amount of heparin is added.
Fig. 4 is a diagram showing a hepatocyte-growth activity of an hHGF when various concentrations of dextran sulfate, dextran and heparin are added to a predetermined amount of the hHGF.
Fig. 5 is a diagram showing hepatocyte-growth activity of an hHGF when various polysaccharides and derivatives thereof are added to a predetermined amount of the hHGF.
Fig. 6 is a diagram showing results of relations between concentrations of a heparin-bound type hHGF and an hHGF to which heparin is not bound, and hepatocyte-growth activi-ties, when cultivation was carried out for 24 hours afteraddition of each sample to be tested.
~ ~ 7 ~
Fig. 7 is a diagram showing results of relations between concentrations of a heparin-bound type hHGF and an hHGF to which heparin is not bound, and hepatocyte-growth activi-ties, when cultivation was carried out for 48 hours after addition of each sample to be tested.
Fig. 8 is a diagram showing inhibition of degradat~on of a heparin-bound type hHGF and dextran sulfate-bound type hHGF.
~ RIPTION OF THE PREFERRED_EMBODIMENTS
In the following, the pxesent invention is explained in detail.
The hHGF to be used in the present invention is a proteinic factor derived from human, having an activity of promoting growth of hepatocyte, and either one obtained by its puri-fication from plasma or obtained by expressing its cDNA may be used. More specifically, for example, it can be obtain-ed by separating and purifying proteinic chemically from plasma of patients with fulminant hepatic failure and puri-fying it according to the method disclosed in Japanese Provisional Patent Publication No. 22526/198~, or by constituting a expression vector containing cDNA which codes the hHGF obtained from cDNA library derived from human placenta and express it in a host such as a CHO cell according to the method disclosed in Japanese Provisional Patent Publication No. 285693/1991.
Such an hHGF is a heterodimeric protein in which a large sub-unit with a molecular weight of about 56,000 to 65,000 and a small sub-unit with a molecular weight of about 32,000 to 35,000 are linked by a disulfide bond, which substance give a band to a molecular weight of about 76,000 to 92,000 by SDS~PAGE under non-reducing conditions, and - 5 - 2 ~ , give main bands to molecular weights of about S6,000 to 65,000 and about 32,000 to 35,000 by SDS-PAGE under reduc~
ing conditions. This hHGF loses its activity of promoting growth of hepatocyte by heat treatment at 80 C for 10 minutes or trypsin or chymotrypsin digestion, and shows strong affinity for heparin. In general, the hHGF to be used in the present invention be~ins to exhibit a hepato-cyte-growth acti.vity at a concentration of about 0 5 to ~
ng/ml, and exhibits a good growth activity at a concentra-tion of about 5 to 10 ng/ml.
In the present invention, the above hHGF and a polysac-charide or a derivative thereof are used i.n combination.
The polysaccharide or a derivative thereof herein mentioned in the present invention means a carbohydrate formed by dehydration and condensation of at least two monosacchar-ides through glycoside linkage, i.e. includes all glycans or a derivative thereof. Such a polysaccharide or a deriv-ative thereof may have a structure in which disaccharide units are repeated as in glycosaminoglycan and there may be suitably used those in which one of the disaccharides com-prises glucosamine or galactosamine ~Science of Life, (~), pp. 306 to 310 (1988)) or a derivative in which a polysaccharide such as glucan is sulfated. More specific-ally, for example, there may be mentioned hyaluronic acid,chondroitin, chondroitin sulfate, dermatan sul~ate, heparan sulfate, keratan sulfate, heparin, dextran and dextran sulfate. Particularly preferably used is a sulfate deriva-tive of a polysaccharide such as heparin~ dextran sulfate, heparan sulfate and chondroitin sulfate.
The polysaccharide or a derivative thereof is preferably used in an excessive amount based on the amount of the hHGF, and the polysaccharide or a derivative thereof is generally used in the range of 102 to 105 mole per mole of the hHGF.
- 6 - ~ J
The hepatocyte-growth agent of the present invention ls mainly used as an injection. The :injection can be prepared according to a conventional method. In that case, a known additive such as human serum album:in and a surfactant may be used in combination. More specifically, for example, it can be prepared by dissolving the composition shown below in a 10 mM phosphate buffer solution (PBS(-)) having a pH
of 7.5, making the total amounk of the mixture up to 5 ml, sterilizing it by a filter of 0.22 ~m and apportioning it to vials, or further lyophilizing and storing the mixture, and suitably dissolving it in distilled water or physio-logical saline when it is used.
~1) 100 ~g of hHGF, 50 mg of human serum albumin and 0.5 mg of Triton X-100 (trade name, produced by, e.g. NACALAI
TESQUE, INC.) (2) 100 ~g of hHGF and 50 mg of human serum albumin (3) 100 ~g of hHGF and 0.5 mg of Triton X-100 (trade name, ditto) (4) 100 ~g of hHGF and 0.5 mg of Tween 80 (trade name, produced by, e.g. NACALAI TESQUE, INC.) (5) 5 mg of heparin (6) 5 mg of heparin, 50 mg of human serum albumin and 0.5 mg of Triton X-100 (trade name, ditto) (7) 100 ~g of hHGF, 5 mg of heparin, 50 mg of human serum 25 albumin and 0.5 mg of Triton X-100 (trade name, ditto) (8) 100 ~g of hHGF, 5 mg o~ heparin and 50 mg o~ human serum albumin ~9) 100 ~g of hHGF, 5 mg of heparin and 0.5 mg of Triton X-100 (trade name, ditto) 30 (10) 100 ~g of hHGF, 5 mq of heparin and 0.5 mg of Tween 80 (trade name, ditto) (11) 100 ~g of hHGF and 5 mg of heparin In the present invention, an injection containing both the hHGF and the polysaccharide or a derivative thereof may be prepared and used. Otherwise, injections containing each of them are prepared, respectively, and after an injection containing the polysaccharide or a derivative thereof is used, an injection containing the hHGF may be used or both injections may be used simultaneously. When the injection containing the hHGF is used in advance, the injection con~
taining the polysaccharide or a derivative thereof is preferably used successively as quick].y as possible.
An amount of the hepatocyte-growth agent of the present invention to be added varies depending on activity of the h~GF which is an active ingredient and a patient to which it is administered, but may be selected from the range of about 0.1 ~g/kg to 1,000 ~g/kg.
EXAMPLES
The present invention is described in detail by referring to Exarnples, but the present invention is not limited to the following Examples so long as it is within the scope of the invention.
Example 1 Heightening activation of hHGF protein by adding heparin According to the Seglen's method (~ethods in Cellbiology, vol. 13, p. 29, Academic Press, New York (1976)), hepato-cytes were isolated from Wistar strain male rats (~ody weigh~: 200 g) by using 0.05 % collagenase ~Type I, trade name, produced by Sigma Co.). The hepatocytes were plated in collagen-coated multiwell plastic dishes (produced by Nunc) having wells with a diameter of 1.55 cm at a density of 5 x 104/0.2 ml/cm2, and single layer culture was carried out at 37 C under a gas phase of air containing 5 %
carbonic acid gas (Tanaka et al., J. Biochem. 84, pp. 937 to 996 (1978)). As a medium for the culture, there was - 8 - ~ 3 used a Williams E medium (trade name, produced by Flow Laboratories, Co., hereinafter abbreviated to as "basic medium") to which 5 ~ fetal bovine serurn (FBS, produced by Filtron in Altona, Australia), 1 ~M dexamethasone, 100 U/ml of penicillin and 100 ~g/ml of streptomycin were added.
Three hours after initiation of the culture, the medium was exchanged with a new basic medium, and after 20 hours, the basic medium was exchanged with a basic mediurn containing no bovine feral serum. After this exchange of the media, heparin (molecular weight: 4,000 to 6,000, produced by Sigma Co.~ was so added that the final concentrations became 0, 50, 100, 200 and 500 ~g/ml, respectively, and then a recombinant hHGF was so added the final concentra-tion became 100 ng/ml. After culture was continued for 20hours, DNA synthesis was measured. The DNA synthesis was examined by adding 3H-thymidine (trade name, produced by Amersham Co.) so that the final concentration became 4 ~Ci/ml (2 Ci/mmole), then continuing culture for 4 hours and measuring uptake of 3H-thymidine to DNA. As a control group, a group to which the hHGF was not added was used.
After labeling with the above culture, cells were washed with a ce-cold PBS(-), 2 % perchloric acid and 95 ~
ethanol each three times. Subse~uently, the cells were air-dried and solubilized with 500 ~1 of lN NaOH. Then, a part thereof was taken out, and a radioactivity was mea-sured. A concentration of the recombinant hHGF was mea-sured by the enzyme immunoassay. An activity value was determined as difference between the uptake amount of 3H-thymidine to hepatocyte DNA from a sample to be tested andthat of the control group (in the following, all activity values of hHGFs were determined b~ this method). The results are shown in Fig. 1. In Flg. 1, the axis of abscissas shows a final concentration of heparin, and the axis of ordinates shows an hHGF activity.
~Ç~Q~ OF THE INVENTIQN
This invention relates to a hepatocyte-growth agent which promotes growth of hepatocyte, more specifically to a hepatocyte-growth agent which comprises a polysaccharide or a derivative thereof and a hepatocyte-growth factor, in which said hepatocyte-growth factor is stabilized and further, its growth activity is heightened.
In recent years, a proteinic factor derived from human, : ` which can promote growth of hepatocyte, namely, a human hepatocyte-growth factor (hereinafter sometimes abbreviated to as "hHGF") has been found in plasma of patients with fulminant hepatic failure (Japanese Provisional Patent Pub-lication No. 22526/1988). Further, there have been propos-ed an amino acid sequence and a gene (cDNA) sequence which codes hHGF protein (Japanese Provisional Patent Publication No. 72883/1991), and a method for producing hHGF protein using this cDNA and a transformant thereof (Japanese Pro-visional Paten~ Publication No. 285693/1991). It has been recognized that such an hHGF has mitogenic acti~ity for hepatocytes in vitro. In order to clarify a mechanism of growth hepatocyte by an hHGF existing in nature or a recom-- 2 - 2~
binant hHGF, the present inventors have studied binding systems of these hHGFs to hepatocyte, and consequently found that most of the hHGFs bound to hepatocyte is washed away with a buffer solution containing a polysaccharide such as glycosaminoglycan and heparin, or a derivative thereof. From the result, it was estimated that a poly-saccharide or a derivative thereof irhibits the binding of hHGF to hepatocyte, uptake of the same to hepatocyte or metabolization process thereof, all of which are considered to be indispensable to induce a hepatocyte-growth activity of the hHGF, and thus, has an action of inhibiting activity of the hHGF.
SUMMARY OF THE INVENTION
The present inventors have further studied influences of a polysaccharide or a derivative thereof exerting on a hepatocyte-growth activity of the hHGF. Namely, they have measured various influences on hepatocyte-growth activities (1) when a polysaccharide or a derivative thereof and the hHGF are mixed and added, (2) when a polysaccharide or a derivative thereof is added and then the hHGF is added, and (3) when the hHGF is added and then a polysaccharide or a derivative thereof is added to hepatocyte prepared by the Seglen's method (Methods in cellbiology, vol. 13, p. 29, Academic Press, New York (1976)).
As a result, it was interestingly found for the first time, which were different from the results estimated in the prior art techniques, that an ability of promoting growth of hepatocyte possessed by the hHGF is extremely strength-ened when a polysaccharide or a derivative thereof and the hHGF are mixed and added, and when a polysaccharide or a derivative thereof is added and then the hHGF is added, and additionally, degradation of the hHGF existing in a medium supernatant is suppressed by adding a polysaccharide or a - 3 ~ 3 derivative thereof to a system of measuring growth of hepatocyte by the hHGF, namely, an hHGF molecule is stabi-lized to accomplish the present invention.
That is, a gist of the present invention resides in a hepatocyte-growth agent which comprises a polysaccharide or a derivative thereof and a hepatocyte-growth factor.
~RI~F ~ESCRIPTIO~ OF THF ~R~WING
Fig. 1 is a diagram showing a relation between a heparin concentration and hHGF activity when hHGF activity is heightened by adding heparin.
Fig. 2 is a diagram showing a relation between an hHGF
concentration and hHGF activity when hHGF activity is heightened by adding a predetermined amount of heparin.
Fig. 3 is a diagram showing inhibition of a labeled hHGF
degradation when a predetermined amount of heparin is added.
Fig. 4 is a diagram showing a hepatocyte-growth activity of an hHGF when various concentrations of dextran sulfate, dextran and heparin are added to a predetermined amount of the hHGF.
Fig. 5 is a diagram showing hepatocyte-growth activity of an hHGF when various polysaccharides and derivatives thereof are added to a predetermined amount of the hHGF.
Fig. 6 is a diagram showing results of relations between concentrations of a heparin-bound type hHGF and an hHGF to which heparin is not bound, and hepatocyte-growth activi-ties, when cultivation was carried out for 24 hours afteraddition of each sample to be tested.
~ ~ 7 ~
Fig. 7 is a diagram showing results of relations between concentrations of a heparin-bound type hHGF and an hHGF to which heparin is not bound, and hepatocyte-growth activi-ties, when cultivation was carried out for 48 hours after addition of each sample to be tested.
Fig. 8 is a diagram showing inhibition of degradat~on of a heparin-bound type hHGF and dextran sulfate-bound type hHGF.
~ RIPTION OF THE PREFERRED_EMBODIMENTS
In the following, the pxesent invention is explained in detail.
The hHGF to be used in the present invention is a proteinic factor derived from human, having an activity of promoting growth of hepatocyte, and either one obtained by its puri-fication from plasma or obtained by expressing its cDNA may be used. More specifically, for example, it can be obtain-ed by separating and purifying proteinic chemically from plasma of patients with fulminant hepatic failure and puri-fying it according to the method disclosed in Japanese Provisional Patent Publication No. 22526/198~, or by constituting a expression vector containing cDNA which codes the hHGF obtained from cDNA library derived from human placenta and express it in a host such as a CHO cell according to the method disclosed in Japanese Provisional Patent Publication No. 285693/1991.
Such an hHGF is a heterodimeric protein in which a large sub-unit with a molecular weight of about 56,000 to 65,000 and a small sub-unit with a molecular weight of about 32,000 to 35,000 are linked by a disulfide bond, which substance give a band to a molecular weight of about 76,000 to 92,000 by SDS~PAGE under non-reducing conditions, and - 5 - 2 ~ , give main bands to molecular weights of about S6,000 to 65,000 and about 32,000 to 35,000 by SDS-PAGE under reduc~
ing conditions. This hHGF loses its activity of promoting growth of hepatocyte by heat treatment at 80 C for 10 minutes or trypsin or chymotrypsin digestion, and shows strong affinity for heparin. In general, the hHGF to be used in the present invention be~ins to exhibit a hepato-cyte-growth acti.vity at a concentration of about 0 5 to ~
ng/ml, and exhibits a good growth activity at a concentra-tion of about 5 to 10 ng/ml.
In the present invention, the above hHGF and a polysac-charide or a derivative thereof are used i.n combination.
The polysaccharide or a derivative thereof herein mentioned in the present invention means a carbohydrate formed by dehydration and condensation of at least two monosacchar-ides through glycoside linkage, i.e. includes all glycans or a derivative thereof. Such a polysaccharide or a deriv-ative thereof may have a structure in which disaccharide units are repeated as in glycosaminoglycan and there may be suitably used those in which one of the disaccharides com-prises glucosamine or galactosamine ~Science of Life, (~), pp. 306 to 310 (1988)) or a derivative in which a polysaccharide such as glucan is sulfated. More specific-ally, for example, there may be mentioned hyaluronic acid,chondroitin, chondroitin sulfate, dermatan sul~ate, heparan sulfate, keratan sulfate, heparin, dextran and dextran sulfate. Particularly preferably used is a sulfate deriva-tive of a polysaccharide such as heparin~ dextran sulfate, heparan sulfate and chondroitin sulfate.
The polysaccharide or a derivative thereof is preferably used in an excessive amount based on the amount of the hHGF, and the polysaccharide or a derivative thereof is generally used in the range of 102 to 105 mole per mole of the hHGF.
- 6 - ~ J
The hepatocyte-growth agent of the present invention ls mainly used as an injection. The :injection can be prepared according to a conventional method. In that case, a known additive such as human serum album:in and a surfactant may be used in combination. More specifically, for example, it can be prepared by dissolving the composition shown below in a 10 mM phosphate buffer solution (PBS(-)) having a pH
of 7.5, making the total amounk of the mixture up to 5 ml, sterilizing it by a filter of 0.22 ~m and apportioning it to vials, or further lyophilizing and storing the mixture, and suitably dissolving it in distilled water or physio-logical saline when it is used.
~1) 100 ~g of hHGF, 50 mg of human serum albumin and 0.5 mg of Triton X-100 (trade name, produced by, e.g. NACALAI
TESQUE, INC.) (2) 100 ~g of hHGF and 50 mg of human serum albumin (3) 100 ~g of hHGF and 0.5 mg of Triton X-100 (trade name, ditto) (4) 100 ~g of hHGF and 0.5 mg of Tween 80 (trade name, produced by, e.g. NACALAI TESQUE, INC.) (5) 5 mg of heparin (6) 5 mg of heparin, 50 mg of human serum albumin and 0.5 mg of Triton X-100 (trade name, ditto) (7) 100 ~g of hHGF, 5 mg of heparin, 50 mg of human serum 25 albumin and 0.5 mg of Triton X-100 (trade name, ditto) (8) 100 ~g of hHGF, 5 mg o~ heparin and 50 mg o~ human serum albumin ~9) 100 ~g of hHGF, 5 mg of heparin and 0.5 mg of Triton X-100 (trade name, ditto) 30 (10) 100 ~g of hHGF, 5 mq of heparin and 0.5 mg of Tween 80 (trade name, ditto) (11) 100 ~g of hHGF and 5 mg of heparin In the present invention, an injection containing both the hHGF and the polysaccharide or a derivative thereof may be prepared and used. Otherwise, injections containing each of them are prepared, respectively, and after an injection containing the polysaccharide or a derivative thereof is used, an injection containing the hHGF may be used or both injections may be used simultaneously. When the injection containing the hHGF is used in advance, the injection con~
taining the polysaccharide or a derivative thereof is preferably used successively as quick].y as possible.
An amount of the hepatocyte-growth agent of the present invention to be added varies depending on activity of the h~GF which is an active ingredient and a patient to which it is administered, but may be selected from the range of about 0.1 ~g/kg to 1,000 ~g/kg.
EXAMPLES
The present invention is described in detail by referring to Exarnples, but the present invention is not limited to the following Examples so long as it is within the scope of the invention.
Example 1 Heightening activation of hHGF protein by adding heparin According to the Seglen's method (~ethods in Cellbiology, vol. 13, p. 29, Academic Press, New York (1976)), hepato-cytes were isolated from Wistar strain male rats (~ody weigh~: 200 g) by using 0.05 % collagenase ~Type I, trade name, produced by Sigma Co.). The hepatocytes were plated in collagen-coated multiwell plastic dishes (produced by Nunc) having wells with a diameter of 1.55 cm at a density of 5 x 104/0.2 ml/cm2, and single layer culture was carried out at 37 C under a gas phase of air containing 5 %
carbonic acid gas (Tanaka et al., J. Biochem. 84, pp. 937 to 996 (1978)). As a medium for the culture, there was - 8 - ~ 3 used a Williams E medium (trade name, produced by Flow Laboratories, Co., hereinafter abbreviated to as "basic medium") to which 5 ~ fetal bovine serurn (FBS, produced by Filtron in Altona, Australia), 1 ~M dexamethasone, 100 U/ml of penicillin and 100 ~g/ml of streptomycin were added.
Three hours after initiation of the culture, the medium was exchanged with a new basic medium, and after 20 hours, the basic medium was exchanged with a basic mediurn containing no bovine feral serum. After this exchange of the media, heparin (molecular weight: 4,000 to 6,000, produced by Sigma Co.~ was so added that the final concentrations became 0, 50, 100, 200 and 500 ~g/ml, respectively, and then a recombinant hHGF was so added the final concentra-tion became 100 ng/ml. After culture was continued for 20hours, DNA synthesis was measured. The DNA synthesis was examined by adding 3H-thymidine (trade name, produced by Amersham Co.) so that the final concentration became 4 ~Ci/ml (2 Ci/mmole), then continuing culture for 4 hours and measuring uptake of 3H-thymidine to DNA. As a control group, a group to which the hHGF was not added was used.
After labeling with the above culture, cells were washed with a ce-cold PBS(-), 2 % perchloric acid and 95 ~
ethanol each three times. Subse~uently, the cells were air-dried and solubilized with 500 ~1 of lN NaOH. Then, a part thereof was taken out, and a radioactivity was mea-sured. A concentration of the recombinant hHGF was mea-sured by the enzyme immunoassay. An activity value was determined as difference between the uptake amount of 3H-thymidine to hepatocyte DNA from a sample to be tested andthat of the control group (in the following, all activity values of hHGFs were determined b~ this method). The results are shown in Fig. 1. In Flg. 1, the axis of abscissas shows a final concentration of heparin, and the axis of ordinates shows an hHGF activity.
9 s~ d 7,! ~ 3 Fig. 2 shows results when heparin (molecular weight: 4,000 to 6,000, produced by Sigma Co.) was so added as a sample to be tested that the final concentration became 100 ~g/ml, and the recombinant hHGF was so added that the final con-centrations became 0, 4.28, 8.75, 17.5, 35, 70 and 140ng/ml, respectively. The axis of abscissas shows a final concentration of the recombinant hHGF when heparin was added, and the axis of ordinates shows an hHGF activity.
In Fig. 2, the curve (l) shows an hHGF activity when heparin was so added that the final concentration became 100 ~g/ml, and the curve (2) shows an hHGF activity when heparin was not added.
From the results in Fig. 1 and Fig. 2, it can be seen that activity of hHGF protein is heightened by adding heparin.
~xam~le 2 Inhibition of hHGF protein degradation by adding heparin According to the Seglen's method (Methods in Cellbiology, vol. 13, p. 29, ~cademic Press, New York (1976)~ shown in Example 1, hepatocytes were separated. The hepatocytes were plated in collagen-coated multiwell plastic dishes (produced by ~lunc) having wells with a diameter of 3.5 cm at a density of 5 x 104/0.2 ml/cm2, and single layer cul-ture was carried out at 37 C under a gas phase of air containing 5 % carbonic acid gas (Tana~a et al., ~ Bio-chem. 84, pp. 937 to 946 (1978)). As a medium for the culture, there was used a Williams E medium (trade name, produced by Flow Laboratories, Co., hereinafter abbreviated to as "basic medium") to which 5 % fetal bovine serum (FBS, produced by Filtron in Altona, Australia), 1 ~M dexametha-sone, 100 U/ml of penicillin and 100 ~g/ml of streptomycin were added.
?, ~ ~3 Three hours after initiation of the culture, the medium was exchanged with a new basic medium, and after 20 hours, the basic medium was washed with PBS(-) containing 0.25 %
gelatin three times. Then, 2 ml of Dulbecco's MEM (herein-after abbreviated to as "Binding medium") containing 0.25 %gelatin and 25 mM hepes was added into each well, and single layer culture was carried out at 37 C for 3 hours under gas phase of gas containing 5 % carbonic acid gas.
Subsequently, the Binding medium was exchanged and 1 ml of a Binding medium was added into each well. Further, hepa-rin (molecular weight: 4,000 to 6,000 produced by Sigma Co.) was so added that the final concentration became 100 ~g/ml. As a control group, a group to which heparin was not added was used. On the other hand, according to the Hunter et al method (Nature 1~4, pp. 495 and 496 (1962)), the recombinant hHGF was labeled by using a carrier-free Na1~5I (3.7 GBq, trade name, produced by NEN Co.). The labeled hHGF obtained (hereinafter abbreviated to as "labeled hHGF"~ was so added into each well that the final concentration became 200 pM. Thereafter, single layer culture was carried out at 37 C under a gas phase of air containing 5 % carbonic acid gas. A culture supernatant was collected 0 minute, 10 minutes, 30 minutes, 60 minutes, 120 minutes and 1~0 minutes after inltiation of the cul ture, and the culture supernatant collected was sufficient-ly chilled in ice. Subsequently, transfer-RNA was so added that the final concentration became 100 ~g/ml, and then trichloroacetic acid tTCA) was so added that the final concentration became 10 %. The sample to be tested thus prepared was incubated for 3 hours under ice-cooling, and then centrifuga'cion of 10,000 G was carried out to collect a supernatant which was used for measurement o~ the amount of the degraded hHGF. In the supernatant thus obtained, the labeled hHGF of which a molecular weight was made lower, namely degraded by incubation with hepatocytes, were contained.
The results are shown in Fig. 3. The axis of abscissas shows time from addition of the labeled hHGF to hepatocyte to collection of the culture supernatant, and the axis of ordinates shows radioactivity of the degraded labeled hHGF.
In Fig. 3, the curve (1) shows the amount of the degraded labeled hHGF when heparin was so added that the final concentration became 100 ~g/ml, and the curve ~2) shows the amount of the degraded labeled hHGF when heparin was not added.
From the results in Fig. 3, it can be understood that degradation of hHGF protein is inhibited effectively by adding heparin.
Example 3 Hightening of hHGF protein by adding dextran sulfate and dextran For dextran sulfate having a molecule structure similar to that of heparin, and dextran having no sulfuric acid group in its molecule, influences on a hepatocyte-growth activity possessed by the hHGF were examined.
In the same manner shown in Example 1, hepatocytes were isolated and cultured.
Three hours after ini~iation of the culture, the medium was exchanged with a new basic medium, and after 20 hours, the basic medium was exchanged with a basic medium containing the recombinant hHGF having a final concentration of 200 ng/ml and 1, 10, 50, 100 or 500 ~g/ml of dextran sulfate ~molecular weight: 8,000, produced by Sigma Co.), dextran (molecular weight: 10,000, produced by Sigma Co.) or heparin (molecular weight: 4,000 to 6,000, produced by Sigma Co.~ and containing no fetal bovine serum. After - 12 ~
culture was continued for 20 hours~ synthesis of DNA was measured. The synthesis of DN~ and the concentration of the recombinant hHGF were measured in the same manner as in Example 1.
The resul~s are shown in Fig. 4. In Fig. 4, the axis of abscissas shows a final concentration of dextran sulfate, dextran or hepaxin added, and the axis of ordinates shows activity of the hHGF.
As shown in Fig. 4, a hepatocyte-growth activity possessed by the hHGF can be strengthened even by adding dextran sulfate or dextran. It can be particularly seen that dextran sulfate significantly strengthens activity of the hHGF similarly as heparin.
Example ~
Heightening activation of hHGF protein by adding various polysaccharide and derivatives thereof For heparin, dextran sulfate and dextran used in Examples described abo~e, and also heparan sulfate, hyaluronic acid, chondroitin and chondroitin sulfates A to E which were used as samples to be tested, influences on a hepatocyte-growth activity possessed by the hHGF were examined.
In the same manner as in Example 1, hepatocytes were isolated. Also in the same manner as in Example 1, these hepatocytes were plated in collagen-coated multiwell plastic dishes (produced by Nunc) having wells with a dia-meter of 1.55 cm at a density of 5 x 104/0.2 ml/cm2, and single layer culture was carried out at 37 C under a gas phase of air containing 5 ~ carbonic acid gas. As a medium for the culture, there was used a Williams E medium (trade name, produced by Flow Laboratories, Co., hereinafter - 13 - ~ J ~
abbreviated to as "basic medium") to which 5 % fetal bovine serum (FBS, produced by Filtron in Altona, Australia), 1 ~M
dexamethasone, 100 U~ml of penicillin and 100 ~g/ml of streptomycin were added. Three hours after initiation of the culture, the medium was exchanged with a basic medium, and after 20 hours, the basic medium was exchanged with a basic medium containing no fetal bovine serum.
Subse~uently, the respective samples to be tested were so added that the final concentrations became 100 ~g/ml, and 200 ng/ml of a recombinant hHGF was added. After culture was continued for 20 hours, DNA synthesis of hepatocytes was measured. The DNA synthesis was examined by the same me~hod described in Example 1. As a control group, a group to which the hHGF was not added was used. After labeling with the above culture, cells were washed with an ice-cold PBS~-), 2 ~ perchloric acid and 95 % ethanol each three times. Subsequently, the cells were air-dried and solubilized with 500 ~1 of lN NaOH. Then, a part thereof was taken out, and a radioactivity was measured. A
concentration of the recombinant hHGF was measured by enzyme immunoassay. An activity value was determined as difference between the uptake amount: of 3H-thymidine to hepatocyte DNA from each sample to be tested and that of the control group. The results are shown in Fig. 5.
In Fig. 5, the àxis of ordinate shows various polysac-charides, glycosaminoglycan and derivatives thereo~, and the axis of abscissas shows hHGF activities. It can be understood that hHGF activities were remarkably heightened particularly by adding heparin, dextran sulfate, heparan sulfate and chondroitin sulfate.
~xample 5 Preparation of polysaccharide- or derivative thereof-bound - 14 ~
type hHGF protein and strengthening of hepatocyte-growth activity thereo~.
The hHGF has strong af~inity for a polysaccharide heparin and dextran sulfate, or a derivative thereof. Therefore, only a polysaccharide- or derivative thereof-bound type hHGF was prepared by mixing the polysaccharide or a deriva-tive thereof with the hHGF, and removing a polysaccharide or a derivative thereof which was not bound to the hHGF.
It has been particularly known that heparin and dextran sulfate exhibit anticoagulant effect on blood in vivo.
However, it can be expected that influences of a simple polysaccharide or a derivative thereof, for example, heparin or dextran sulfate which are not bound to the hHGF, on living bodies are extremely suppressed by using the present method. Further, it can be seen that the hHGF to which such a molecule is bound induces a hepatocyte-growth acti~ity extremely strongly similarly as shown in Example 1 as compared with the case when only the hHGF is added.
In the following, a method for preparing polysaccharide- or derivative thereof-bound type hHGF protein and strength-ening of an hepatocyte-growth activity thereof are de-scribed.
To 1 ml of a PBS(-) solution containing 1 mg of the recom-binant hHGF protein was added 100 ~l of ~ PBS(-) solution containing heparin ~molecular weight: 4,000 to 6,000, produced by Sigma Co.) so as to have a final concentration of 50 mg/ml. After the mixture was incubated at 4 C for 24 hours, heparin which was not bound to the hHGF was removed by gel filtration procedure using a Sephadex G-50 column (trade name, manufactured by Pharmacia Co.).
Namely, after the Sephadex G-50 column (trade name, manu-factured by Pharmacia Co.) (1.5 x 12 cm) equilibrated witha PBS(-) solution (hereinafter abbreviated to as "eluting ~uffer solution") containing a final concentration of 0.01 % of Tween 80 (trade name, produced by NACALAI TESQUE, INC.) was charged with a mixture of heparin and the hHGF, the column was charged with the eluting buffer solution.
The hHGF protein (hereinafter abbreviated as "heparin-bound type hHGF") to which heparin was bound was collected in a void volume fraction of the same column. On the other hand, since the heparin (produced by Sigma Co.) used in the present procedure having a low molecular weight of 9,000 to 6,000, it was not eluted in the void volume fraction in which the heparin-bound type hHGF was collected.
Next, the hepatocyte-growth activity of the heparin-bound type hHGF was measured.
In the same manner shown in Example 1, hepatocytes were isolated and cultured. Three hours after initiation of the culture, the medium was exchanged with a basic medium, and after 20 hours, the basic medium was exchanged with a basic medium containing no bovine feral serum (produced by Flow Laboratories Co.). ~fter this exchange of the media, the heparin-bound type hHGF having a final concentration of 0, 0.5, 2, 10, 50, 100 or 300 ~g/ml, or the hHGF to which heparin was not bound was added as a sample to be tested.
After culture was continued for 24 hours or 48 hours, synthesis of DNA was measured. The synthesis of DNA was examined by adding 3H-thymidine ~trade name, produced by Amersham Co.) so that the ~inal concentration became 4 ~Ci/ml (2 Ci/mmole), then continuing culture at 37 'C for 5 hours, and measuring uptake of 3H-thymidine to DNA. As a control group, a group to which the hHGF was not added was used. After labeling with the above culture, cells were washed with an ice-cold PBS(-), 2 % perchloric acid and 95 % ethanol each three times. Subsequently, the cells were air-dried and solubilized with 500 ~l of lN NaOH. Then, a part thereof was taken out, and the radioactivity was 2~2~
measured. The concentrations of the recornbinant hHGF and the heparin-bound type hHGF were measured by the enzyme lmmunoassay in the same manner as in Example 1. The activity value was determined as di~ference between the uptake amount of 3H-thymidine to hepatocyte DNA from a sample to be tested and that of the control group.
The results obtained by culture for 24 hours after the samples to be tested were added are shown in Fig. 6, and the results obtained by culture for ~8 hours are shown in Fig. 7. In Fig. 6 and Fig. 7, the axes of abscissas show final concentrations of heparin, and the axes of ordinates show activities of the hHGF.
As shown in Fig. 6 and Fig. 7, it can be observed that the heparin-bound type hHGF strengthens and maintains a high hepatocyte-growth activity by adding it in amounts ranging from low concentration to high concentration, as compared with the hHGF to which heparin is not bound. It can be particularly seen that the heparin-bound type hHGF main-tains high activity stably while the hHGF to which heparin is not bound extremely decreases a hepatocyte-growth activity when added at a concentration of 50 to 300 ng/ml.
E~mple 6 Preparations various polysaccharides- and derivatives thereof-bound type hHGF proteins and inhibition of the hHGF
protein-degradation In the same manner as in Example 2, according to the Hunter et al. method, a recombinant hHGF was labeled by using Nal25I (3.7 GBq, trade name, produced by NEN Co.). To 200 ~l of a PBS(-) solution containing 3 ~g of the labeled recombinant hHGF protein obtained was added 200 ~l of a PBS(-) solution containing heparin (molecular weight: 4,000 ~7~
to 6,000, produced by Sigma Co.) or dextran sulfate ~mole-cular weight: 8,000, produced by Sigma Co.), so as to have a final concentration of 50 rng/ml. After the mixture was incubated at ~ C for 24 hours, heparin or dextran sulfate which was not bound to the hHGF was removed by gel filtra-tion procedure using a Sephadex G-50 column (trade name, manufactured by Pharmacia Co.). Namely, the Sephadex G-50 column (trade name, manufactured by Pharmacia Co.) (1.5 x 12 cm) was equilibrated with a PBS(-) solution containing a final concentration of 0.01 % of Tween ~0 (trade name, produced by NACALAI TESQUE, INC.) (hereinafter abbreviated to as l'eluting buffer solution"). The column was charged with a mixture of heparin or dextran sulfate and the h~GF, which were eluted with the eluting buffer solution. The labeled hHGF protein (hereinafter abbreviated as "heparin-bound type 125I--hHGF" or "dextran sulfate-bound type 125I-hHGF") which was bound to heparin or dextran sulfate mole-cules was collected in void volume fraction of the same column.
Next, hepatocytes were prepared in the same manner shown in Example 2.
That is, according to the Seglen method, hepatocytes were plated in collagen-coated multiwell plastic dishes (pro-duced by Nunc) having wells with a diameter of 3.5 cm at a density of 5 x 104/0.2 ml/cm2, and single layer culture was carried out at 37 C under a gas phase of air containing 5 % carbonic acid gas. As a medium for the culture, there was used a Williams E medium (~rade name, produced by Flow Laboratories, Co., hereinafter abbreviated to as "basic medium") to which 5 % fetal bovine serum ~FBS, produced by Filtron in Altona, Australia), 1 ~M dexamethasone, 100 U/ml of penicillin and 100 ~lg/ml of streptomycin were added Three hours after initiation of the culture, the medium was exchanged with a basic medium, and after 20 hours, the basic medium was washed with PBS(-) con-taining 0.25 % gela-tin three -times. Then, 2 ml of the above Binding medium was added to each well, and single layer culture was carri-ed out at 37 C for 3 hours under a gas phase of air con-taining 5 % carbonic acid gas. Thereafter, the Bindingmedium was exchanged with 1 ml of a Binding medium which was added to each well.
To the hepatocytes prepared, heparin-bound type 125I-hHGF
or dextran sulfate-bound type 125I-hHGF was so added as a sample to be tested that the final concentration hecame 200 pM. As a control group, a group of only l25I-hHGF was used.
Then, single layer culture was carried out at 37 C under a gas phase of air containing 5 % carbonic acid gas. A
culture supernatant was collected at 0 minute, 10 minutes, 30 minutes, 60 minutes, 120 minutes, 180 minutes and 360 minutes after initiation of the culture, and the culture supernatant collected was sufficiently chilled in ice.
Subsequently, transfer RNA was so added that the final concentration became 100 ~g/ml, and then trichloroacetic acid (TCA) was so added that the final concentration became 10 %. Each sample to be tested thus prepared was incubated for 3 hours under ice-cooling, and then centrifugation of 10,000 G was carried out at ~ C to collect a supernatant and a precipitating fraction. In the supexnatant thus obtained (hereinafter referred to "TCA-solubilizing fraction"), the labeled hHG~ of which a molecular weight was made lower, namely degradated by incubation with hepatocytes, was contained. On the other hand, in the precipitating fraction ~hereinafter referred to "TCA-pre-cipitating fraction"), the hHGF which was not degraded was contained. Radioactivities of the TCA-solubilizing fraction and TCA-precipitating fraction obtained were measured to calculate a ratio thereof.
2~2~3 The results are shown in Fig. 8. Fig. 8(A) shows a case when only 125I-hHGF was added, Fig. 8(B) a case when the heparin-bound type l25I-hHGF was added, and Fig. ~(C) a case when the dextran sulfate-bound type 125I-hHGF. The axis of abscissas shows time from addition of the sample to be tested to hepatocytes to collection of the culture supernatant, and the axis of ordinate shows a ratio of radioactivity of the TCA-solubilizing fraction and the TCA-precipitating fraction to the total radioactivity.
As shown in Fig. 8(B) and Fig. 8(C), it can be understood that degradation of hHGF molecules which was bound to heparin or dextran sulfate is inhibited extremely by adding heparin-bound ~ype or dextran sulfate-bound type hHGF.
~xample 7 Promotion of liver regeneration in rats by hHGF to which heparin is added After operation for excising 2/3 of livers of rats (body weight: about 200 g) under anesthesia was carried out, an osmotic pressure pump ALZET 2001 (trade name, produced by ALZET) filled with 200 ~l of a sample solution to be tested and previously stored at 37 C overnight was cannulated to cervical veins, and the sample solution to be tested was continuously fed into venous blood at a rate of 1 ~1 per hour. After 5 days, the rats were killed, and the liver weights were measured.
The sample solution to be tested was a buffer solution with a pH of 7.5 containing 10 mM sodium phosphate and 0.7 M
sodium chloride. As the sample solution to be tested, a solution containing 0.8 ~g/ml of the recombinant hHGF was used in the hHGF-administered group (6 rats), and a solu-tion containing 5 ~g/ml of heparin (molecular weight: 9,000 - 20 - 2~
to 6,000, produced by Sigma Co.) in addition to the recom-binant hHGF was used in the hHGF heparin-administered group (S rats). The buffer solution-administered group (6 rats) was designated as a control group.
~s shown in Table 1, the liver regeneration rate of the hHGF-administered group was significantly higher (P < O.OS) as compared with that of the buffer solution-administered group, and the rate of the hHGF-heparin-administered group was significantly higher (P < 0.05) as compared even with that of the hHGF-administered group. Thus, it can be understood that heparin promotes action of the hHGF even in growth of hepatocyte in animal bodies. The liver regeneration rate was calculated according to the following formula:
Regeneration rate =
Total weight of _ IWeight of liver _ Weight of reenerated liver _lest~m~te~ excised liYe~
20Weight of excised liver Weight of liver estimated =
Body weight x Ratio of liver weight to body weight*
* Ratio of liver weight to body weight of rat which underwent a false operation (only celiotomy without excising liver) after 5 days ~0.0431 in the present Example) 30~L~_1 Liver regeneration rate Sample solution t _ e tested Liver reqeneration rate (O~
Buffer solution _ 88.9 + 5.3_ ¦
h~GF 108 8 + 4 2 hHGF-heparin _ 124.6 ~ S.S
- 21 - 2~ 3 In the prior art, there have not been known existence of a factor of highly ac.tivating or highly stabilizing such a protein for utilizing an hHGF industrially, and a method of utilization thereof.
As shown in the present invention, by using a polysac-charide or a derivative thereof and an hHGF in combination, activity of the hHGF is strengthened stability of an hHGF
molecule is improved. As a result, effects of the hHGF on liver regeneration in the case of liver disorders in vivo can be further improved. Also, by using a polysaccharide or a derivative thereof according to the present invention, storage stability of a hHGF preparation can be expected.
In Fig. 2, the curve (l) shows an hHGF activity when heparin was so added that the final concentration became 100 ~g/ml, and the curve (2) shows an hHGF activity when heparin was not added.
From the results in Fig. 1 and Fig. 2, it can be seen that activity of hHGF protein is heightened by adding heparin.
~xam~le 2 Inhibition of hHGF protein degradation by adding heparin According to the Seglen's method (Methods in Cellbiology, vol. 13, p. 29, ~cademic Press, New York (1976)~ shown in Example 1, hepatocytes were separated. The hepatocytes were plated in collagen-coated multiwell plastic dishes (produced by ~lunc) having wells with a diameter of 3.5 cm at a density of 5 x 104/0.2 ml/cm2, and single layer cul-ture was carried out at 37 C under a gas phase of air containing 5 % carbonic acid gas (Tana~a et al., ~ Bio-chem. 84, pp. 937 to 946 (1978)). As a medium for the culture, there was used a Williams E medium (trade name, produced by Flow Laboratories, Co., hereinafter abbreviated to as "basic medium") to which 5 % fetal bovine serum (FBS, produced by Filtron in Altona, Australia), 1 ~M dexametha-sone, 100 U/ml of penicillin and 100 ~g/ml of streptomycin were added.
?, ~ ~3 Three hours after initiation of the culture, the medium was exchanged with a new basic medium, and after 20 hours, the basic medium was washed with PBS(-) containing 0.25 %
gelatin three times. Then, 2 ml of Dulbecco's MEM (herein-after abbreviated to as "Binding medium") containing 0.25 %gelatin and 25 mM hepes was added into each well, and single layer culture was carried out at 37 C for 3 hours under gas phase of gas containing 5 % carbonic acid gas.
Subsequently, the Binding medium was exchanged and 1 ml of a Binding medium was added into each well. Further, hepa-rin (molecular weight: 4,000 to 6,000 produced by Sigma Co.) was so added that the final concentration became 100 ~g/ml. As a control group, a group to which heparin was not added was used. On the other hand, according to the Hunter et al method (Nature 1~4, pp. 495 and 496 (1962)), the recombinant hHGF was labeled by using a carrier-free Na1~5I (3.7 GBq, trade name, produced by NEN Co.). The labeled hHGF obtained (hereinafter abbreviated to as "labeled hHGF"~ was so added into each well that the final concentration became 200 pM. Thereafter, single layer culture was carried out at 37 C under a gas phase of air containing 5 % carbonic acid gas. A culture supernatant was collected 0 minute, 10 minutes, 30 minutes, 60 minutes, 120 minutes and 1~0 minutes after inltiation of the cul ture, and the culture supernatant collected was sufficient-ly chilled in ice. Subsequently, transfer-RNA was so added that the final concentration became 100 ~g/ml, and then trichloroacetic acid tTCA) was so added that the final concentration became 10 %. The sample to be tested thus prepared was incubated for 3 hours under ice-cooling, and then centrifuga'cion of 10,000 G was carried out to collect a supernatant which was used for measurement o~ the amount of the degraded hHGF. In the supernatant thus obtained, the labeled hHGF of which a molecular weight was made lower, namely degraded by incubation with hepatocytes, were contained.
The results are shown in Fig. 3. The axis of abscissas shows time from addition of the labeled hHGF to hepatocyte to collection of the culture supernatant, and the axis of ordinates shows radioactivity of the degraded labeled hHGF.
In Fig. 3, the curve (1) shows the amount of the degraded labeled hHGF when heparin was so added that the final concentration became 100 ~g/ml, and the curve ~2) shows the amount of the degraded labeled hHGF when heparin was not added.
From the results in Fig. 3, it can be understood that degradation of hHGF protein is inhibited effectively by adding heparin.
Example 3 Hightening of hHGF protein by adding dextran sulfate and dextran For dextran sulfate having a molecule structure similar to that of heparin, and dextran having no sulfuric acid group in its molecule, influences on a hepatocyte-growth activity possessed by the hHGF were examined.
In the same manner shown in Example 1, hepatocytes were isolated and cultured.
Three hours after ini~iation of the culture, the medium was exchanged with a new basic medium, and after 20 hours, the basic medium was exchanged with a basic medium containing the recombinant hHGF having a final concentration of 200 ng/ml and 1, 10, 50, 100 or 500 ~g/ml of dextran sulfate ~molecular weight: 8,000, produced by Sigma Co.), dextran (molecular weight: 10,000, produced by Sigma Co.) or heparin (molecular weight: 4,000 to 6,000, produced by Sigma Co.~ and containing no fetal bovine serum. After - 12 ~
culture was continued for 20 hours~ synthesis of DNA was measured. The synthesis of DN~ and the concentration of the recombinant hHGF were measured in the same manner as in Example 1.
The resul~s are shown in Fig. 4. In Fig. 4, the axis of abscissas shows a final concentration of dextran sulfate, dextran or hepaxin added, and the axis of ordinates shows activity of the hHGF.
As shown in Fig. 4, a hepatocyte-growth activity possessed by the hHGF can be strengthened even by adding dextran sulfate or dextran. It can be particularly seen that dextran sulfate significantly strengthens activity of the hHGF similarly as heparin.
Example ~
Heightening activation of hHGF protein by adding various polysaccharide and derivatives thereof For heparin, dextran sulfate and dextran used in Examples described abo~e, and also heparan sulfate, hyaluronic acid, chondroitin and chondroitin sulfates A to E which were used as samples to be tested, influences on a hepatocyte-growth activity possessed by the hHGF were examined.
In the same manner as in Example 1, hepatocytes were isolated. Also in the same manner as in Example 1, these hepatocytes were plated in collagen-coated multiwell plastic dishes (produced by Nunc) having wells with a dia-meter of 1.55 cm at a density of 5 x 104/0.2 ml/cm2, and single layer culture was carried out at 37 C under a gas phase of air containing 5 ~ carbonic acid gas. As a medium for the culture, there was used a Williams E medium (trade name, produced by Flow Laboratories, Co., hereinafter - 13 - ~ J ~
abbreviated to as "basic medium") to which 5 % fetal bovine serum (FBS, produced by Filtron in Altona, Australia), 1 ~M
dexamethasone, 100 U~ml of penicillin and 100 ~g/ml of streptomycin were added. Three hours after initiation of the culture, the medium was exchanged with a basic medium, and after 20 hours, the basic medium was exchanged with a basic medium containing no fetal bovine serum.
Subse~uently, the respective samples to be tested were so added that the final concentrations became 100 ~g/ml, and 200 ng/ml of a recombinant hHGF was added. After culture was continued for 20 hours, DNA synthesis of hepatocytes was measured. The DNA synthesis was examined by the same me~hod described in Example 1. As a control group, a group to which the hHGF was not added was used. After labeling with the above culture, cells were washed with an ice-cold PBS~-), 2 ~ perchloric acid and 95 % ethanol each three times. Subsequently, the cells were air-dried and solubilized with 500 ~1 of lN NaOH. Then, a part thereof was taken out, and a radioactivity was measured. A
concentration of the recombinant hHGF was measured by enzyme immunoassay. An activity value was determined as difference between the uptake amount: of 3H-thymidine to hepatocyte DNA from each sample to be tested and that of the control group. The results are shown in Fig. 5.
In Fig. 5, the àxis of ordinate shows various polysac-charides, glycosaminoglycan and derivatives thereo~, and the axis of abscissas shows hHGF activities. It can be understood that hHGF activities were remarkably heightened particularly by adding heparin, dextran sulfate, heparan sulfate and chondroitin sulfate.
~xample 5 Preparation of polysaccharide- or derivative thereof-bound - 14 ~
type hHGF protein and strengthening of hepatocyte-growth activity thereo~.
The hHGF has strong af~inity for a polysaccharide heparin and dextran sulfate, or a derivative thereof. Therefore, only a polysaccharide- or derivative thereof-bound type hHGF was prepared by mixing the polysaccharide or a deriva-tive thereof with the hHGF, and removing a polysaccharide or a derivative thereof which was not bound to the hHGF.
It has been particularly known that heparin and dextran sulfate exhibit anticoagulant effect on blood in vivo.
However, it can be expected that influences of a simple polysaccharide or a derivative thereof, for example, heparin or dextran sulfate which are not bound to the hHGF, on living bodies are extremely suppressed by using the present method. Further, it can be seen that the hHGF to which such a molecule is bound induces a hepatocyte-growth acti~ity extremely strongly similarly as shown in Example 1 as compared with the case when only the hHGF is added.
In the following, a method for preparing polysaccharide- or derivative thereof-bound type hHGF protein and strength-ening of an hepatocyte-growth activity thereof are de-scribed.
To 1 ml of a PBS(-) solution containing 1 mg of the recom-binant hHGF protein was added 100 ~l of ~ PBS(-) solution containing heparin ~molecular weight: 4,000 to 6,000, produced by Sigma Co.) so as to have a final concentration of 50 mg/ml. After the mixture was incubated at 4 C for 24 hours, heparin which was not bound to the hHGF was removed by gel filtration procedure using a Sephadex G-50 column (trade name, manufactured by Pharmacia Co.).
Namely, after the Sephadex G-50 column (trade name, manu-factured by Pharmacia Co.) (1.5 x 12 cm) equilibrated witha PBS(-) solution (hereinafter abbreviated to as "eluting ~uffer solution") containing a final concentration of 0.01 % of Tween 80 (trade name, produced by NACALAI TESQUE, INC.) was charged with a mixture of heparin and the hHGF, the column was charged with the eluting buffer solution.
The hHGF protein (hereinafter abbreviated as "heparin-bound type hHGF") to which heparin was bound was collected in a void volume fraction of the same column. On the other hand, since the heparin (produced by Sigma Co.) used in the present procedure having a low molecular weight of 9,000 to 6,000, it was not eluted in the void volume fraction in which the heparin-bound type hHGF was collected.
Next, the hepatocyte-growth activity of the heparin-bound type hHGF was measured.
In the same manner shown in Example 1, hepatocytes were isolated and cultured. Three hours after initiation of the culture, the medium was exchanged with a basic medium, and after 20 hours, the basic medium was exchanged with a basic medium containing no bovine feral serum (produced by Flow Laboratories Co.). ~fter this exchange of the media, the heparin-bound type hHGF having a final concentration of 0, 0.5, 2, 10, 50, 100 or 300 ~g/ml, or the hHGF to which heparin was not bound was added as a sample to be tested.
After culture was continued for 24 hours or 48 hours, synthesis of DNA was measured. The synthesis of DNA was examined by adding 3H-thymidine ~trade name, produced by Amersham Co.) so that the ~inal concentration became 4 ~Ci/ml (2 Ci/mmole), then continuing culture at 37 'C for 5 hours, and measuring uptake of 3H-thymidine to DNA. As a control group, a group to which the hHGF was not added was used. After labeling with the above culture, cells were washed with an ice-cold PBS(-), 2 % perchloric acid and 95 % ethanol each three times. Subsequently, the cells were air-dried and solubilized with 500 ~l of lN NaOH. Then, a part thereof was taken out, and the radioactivity was 2~2~
measured. The concentrations of the recornbinant hHGF and the heparin-bound type hHGF were measured by the enzyme lmmunoassay in the same manner as in Example 1. The activity value was determined as di~ference between the uptake amount of 3H-thymidine to hepatocyte DNA from a sample to be tested and that of the control group.
The results obtained by culture for 24 hours after the samples to be tested were added are shown in Fig. 6, and the results obtained by culture for ~8 hours are shown in Fig. 7. In Fig. 6 and Fig. 7, the axes of abscissas show final concentrations of heparin, and the axes of ordinates show activities of the hHGF.
As shown in Fig. 6 and Fig. 7, it can be observed that the heparin-bound type hHGF strengthens and maintains a high hepatocyte-growth activity by adding it in amounts ranging from low concentration to high concentration, as compared with the hHGF to which heparin is not bound. It can be particularly seen that the heparin-bound type hHGF main-tains high activity stably while the hHGF to which heparin is not bound extremely decreases a hepatocyte-growth activity when added at a concentration of 50 to 300 ng/ml.
E~mple 6 Preparations various polysaccharides- and derivatives thereof-bound type hHGF proteins and inhibition of the hHGF
protein-degradation In the same manner as in Example 2, according to the Hunter et al. method, a recombinant hHGF was labeled by using Nal25I (3.7 GBq, trade name, produced by NEN Co.). To 200 ~l of a PBS(-) solution containing 3 ~g of the labeled recombinant hHGF protein obtained was added 200 ~l of a PBS(-) solution containing heparin (molecular weight: 4,000 ~7~
to 6,000, produced by Sigma Co.) or dextran sulfate ~mole-cular weight: 8,000, produced by Sigma Co.), so as to have a final concentration of 50 rng/ml. After the mixture was incubated at ~ C for 24 hours, heparin or dextran sulfate which was not bound to the hHGF was removed by gel filtra-tion procedure using a Sephadex G-50 column (trade name, manufactured by Pharmacia Co.). Namely, the Sephadex G-50 column (trade name, manufactured by Pharmacia Co.) (1.5 x 12 cm) was equilibrated with a PBS(-) solution containing a final concentration of 0.01 % of Tween ~0 (trade name, produced by NACALAI TESQUE, INC.) (hereinafter abbreviated to as l'eluting buffer solution"). The column was charged with a mixture of heparin or dextran sulfate and the h~GF, which were eluted with the eluting buffer solution. The labeled hHGF protein (hereinafter abbreviated as "heparin-bound type 125I--hHGF" or "dextran sulfate-bound type 125I-hHGF") which was bound to heparin or dextran sulfate mole-cules was collected in void volume fraction of the same column.
Next, hepatocytes were prepared in the same manner shown in Example 2.
That is, according to the Seglen method, hepatocytes were plated in collagen-coated multiwell plastic dishes (pro-duced by Nunc) having wells with a diameter of 3.5 cm at a density of 5 x 104/0.2 ml/cm2, and single layer culture was carried out at 37 C under a gas phase of air containing 5 % carbonic acid gas. As a medium for the culture, there was used a Williams E medium (~rade name, produced by Flow Laboratories, Co., hereinafter abbreviated to as "basic medium") to which 5 % fetal bovine serum ~FBS, produced by Filtron in Altona, Australia), 1 ~M dexamethasone, 100 U/ml of penicillin and 100 ~lg/ml of streptomycin were added Three hours after initiation of the culture, the medium was exchanged with a basic medium, and after 20 hours, the basic medium was washed with PBS(-) con-taining 0.25 % gela-tin three -times. Then, 2 ml of the above Binding medium was added to each well, and single layer culture was carri-ed out at 37 C for 3 hours under a gas phase of air con-taining 5 % carbonic acid gas. Thereafter, the Bindingmedium was exchanged with 1 ml of a Binding medium which was added to each well.
To the hepatocytes prepared, heparin-bound type 125I-hHGF
or dextran sulfate-bound type 125I-hHGF was so added as a sample to be tested that the final concentration hecame 200 pM. As a control group, a group of only l25I-hHGF was used.
Then, single layer culture was carried out at 37 C under a gas phase of air containing 5 % carbonic acid gas. A
culture supernatant was collected at 0 minute, 10 minutes, 30 minutes, 60 minutes, 120 minutes, 180 minutes and 360 minutes after initiation of the culture, and the culture supernatant collected was sufficiently chilled in ice.
Subsequently, transfer RNA was so added that the final concentration became 100 ~g/ml, and then trichloroacetic acid (TCA) was so added that the final concentration became 10 %. Each sample to be tested thus prepared was incubated for 3 hours under ice-cooling, and then centrifugation of 10,000 G was carried out at ~ C to collect a supernatant and a precipitating fraction. In the supexnatant thus obtained (hereinafter referred to "TCA-solubilizing fraction"), the labeled hHG~ of which a molecular weight was made lower, namely degradated by incubation with hepatocytes, was contained. On the other hand, in the precipitating fraction ~hereinafter referred to "TCA-pre-cipitating fraction"), the hHGF which was not degraded was contained. Radioactivities of the TCA-solubilizing fraction and TCA-precipitating fraction obtained were measured to calculate a ratio thereof.
2~2~3 The results are shown in Fig. 8. Fig. 8(A) shows a case when only 125I-hHGF was added, Fig. 8(B) a case when the heparin-bound type l25I-hHGF was added, and Fig. ~(C) a case when the dextran sulfate-bound type 125I-hHGF. The axis of abscissas shows time from addition of the sample to be tested to hepatocytes to collection of the culture supernatant, and the axis of ordinate shows a ratio of radioactivity of the TCA-solubilizing fraction and the TCA-precipitating fraction to the total radioactivity.
As shown in Fig. 8(B) and Fig. 8(C), it can be understood that degradation of hHGF molecules which was bound to heparin or dextran sulfate is inhibited extremely by adding heparin-bound ~ype or dextran sulfate-bound type hHGF.
~xample 7 Promotion of liver regeneration in rats by hHGF to which heparin is added After operation for excising 2/3 of livers of rats (body weight: about 200 g) under anesthesia was carried out, an osmotic pressure pump ALZET 2001 (trade name, produced by ALZET) filled with 200 ~l of a sample solution to be tested and previously stored at 37 C overnight was cannulated to cervical veins, and the sample solution to be tested was continuously fed into venous blood at a rate of 1 ~1 per hour. After 5 days, the rats were killed, and the liver weights were measured.
The sample solution to be tested was a buffer solution with a pH of 7.5 containing 10 mM sodium phosphate and 0.7 M
sodium chloride. As the sample solution to be tested, a solution containing 0.8 ~g/ml of the recombinant hHGF was used in the hHGF-administered group (6 rats), and a solu-tion containing 5 ~g/ml of heparin (molecular weight: 9,000 - 20 - 2~
to 6,000, produced by Sigma Co.) in addition to the recom-binant hHGF was used in the hHGF heparin-administered group (S rats). The buffer solution-administered group (6 rats) was designated as a control group.
~s shown in Table 1, the liver regeneration rate of the hHGF-administered group was significantly higher (P < O.OS) as compared with that of the buffer solution-administered group, and the rate of the hHGF-heparin-administered group was significantly higher (P < 0.05) as compared even with that of the hHGF-administered group. Thus, it can be understood that heparin promotes action of the hHGF even in growth of hepatocyte in animal bodies. The liver regeneration rate was calculated according to the following formula:
Regeneration rate =
Total weight of _ IWeight of liver _ Weight of reenerated liver _lest~m~te~ excised liYe~
20Weight of excised liver Weight of liver estimated =
Body weight x Ratio of liver weight to body weight*
* Ratio of liver weight to body weight of rat which underwent a false operation (only celiotomy without excising liver) after 5 days ~0.0431 in the present Example) 30~L~_1 Liver regeneration rate Sample solution t _ e tested Liver reqeneration rate (O~
Buffer solution _ 88.9 + 5.3_ ¦
h~GF 108 8 + 4 2 hHGF-heparin _ 124.6 ~ S.S
- 21 - 2~ 3 In the prior art, there have not been known existence of a factor of highly ac.tivating or highly stabilizing such a protein for utilizing an hHGF industrially, and a method of utilization thereof.
As shown in the present invention, by using a polysac-charide or a derivative thereof and an hHGF in combination, activity of the hHGF is strengthened stability of an hHGF
molecule is improved. As a result, effects of the hHGF on liver regeneration in the case of liver disorders in vivo can be further improved. Also, by using a polysaccharide or a derivative thereof according to the present invention, storage stability of a hHGF preparation can be expected.
Claims (21)
1. A hepatocyte-growth agent which comprises a polysac-charide or a derivative thereof and a hepatocyte-growth factor.
2. The agent according to Claim 1, wherein the polysac-charide is glycosaminoglycan.
3. The agent according to Claim 1, wherein the derivative of the polysaccharide is a sulfuric acid derivative.
4. The agent according to Claim 3, wherein the poly-saccharide is glycosaminoglycan.
5. A hepatocyte-growth agent which comprises at least one compound selected from heparin, dextran sulfate, heparan sulfate, chondroitin sulfate, and a hepatocyte-growth factor.
6. The agent according to Claim 1, wherein the polysac-chaxide or a derivative thereof is bound to a hepatocyte-growth factor.
7. The agent according to Claim 1, which is in the form of an injection.
8. A method for heightening activity of a hepatocyte-growth factor which comprises using a polysaccharide or a derivative thereof.
9. The method according to Claim 8, wherein the polysac-charide is glycosaminoglycan.
10. The method according to Claim 8, wherein the deriva-tive of the polysaccharide is a sulfuric acid derivative.
11. The method according to Claim 10, wherein the deriva-tive of the polysaccharide is glycosaminoglycan.
12. A method for heightening activity of a hepatocyte-growth factor which comprises using at least one compound selected from heparin, dextran sulfate, heparan sulfate and chondroitin sulfate.
13. A method for stabilizing a hepatocyte-growth factor which comprises using a polysaccharide or a derivative thereof.
14. The method according to Claim 13, wherein the polysac-charide is glycosaminoglycan.
15. The method according to Claim 11, wherein the deriva-tive of the polysaccharide is a sulfuric acid derivative.
16. The method according to Claim 15, wherein the polysac-charide is glycosaminoglycan.
17. A method for stabilizing a hepatocyte-growth factor which comprises using at least one compound selected from heparin, dextran sulfate, heparan sulfate, chondroitin sulfate and a hepatocyte-growth factor.
18. A pharmaceutical composition for growing hepatocyte in human, which comprises:
an effective amount of a hepatocyte-growth factor, and a polysaccharide or a derivative thereof in a molar excessive amount with respect to the hepatocyte-growth factor.
an effective amount of a hepatocyte-growth factor, and a polysaccharide or a derivative thereof in a molar excessive amount with respect to the hepatocyte-growth factor.
19. A composition according to claim 18, wherein the polysaccharide or derivative thereof is at least one member selec-ted from the group consisting of hyaluronic acid, chondroitin, chondroitin sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, heparin, dextran and dextran sulfate and is contained in an amount of 102 to 105 moles per mole of the hepatocyte-growth factor.
20. A composition according to claim 19, which further comprises a pharmaceutically acceptable diluent.
21. A composition according to claim 18 or 19, which is in the form of injection and contains a pharmaceutically accept-able liquid diluent.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP131271/1991 | 1991-06-03 | ||
| JP13127191 | 1991-06-03 | ||
| JP38122/1992 | 1992-02-25 | ||
| JP3812292 | 1992-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2070263A1 true CA2070263A1 (en) | 1992-12-04 |
Family
ID=26377318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002070263A Abandoned CA2070263A1 (en) | 1991-06-03 | 1992-06-02 | Hepatocyte-growth agent |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5545722A (en) |
| EP (1) | EP0517182B1 (en) |
| KR (1) | KR100210698B1 (en) |
| AT (1) | ATE143810T1 (en) |
| CA (1) | CA2070263A1 (en) |
| DE (1) | DE69214355T2 (en) |
| ES (1) | ES2094848T3 (en) |
| HU (1) | HUT62315A (en) |
| TW (1) | TW318142B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464815A (en) * | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629287A (en) * | 1991-01-18 | 1997-05-13 | University College London | Depot formulations |
| US5610148A (en) * | 1991-01-18 | 1997-03-11 | University College London | Macroscopically oriented cell adhesion protein for wound treatment |
| TW318142B (en) * | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
| GB9306255D0 (en) * | 1993-03-25 | 1993-05-19 | Cancer Res Campaign Tech | Heparan sulphate oligosaccharides having hepatocyte growth factor binding affinity |
| CA2171562A1 (en) * | 1993-09-10 | 1995-03-16 | Carla Cerami | Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites |
| US6756358B2 (en) | 1994-08-19 | 2004-06-29 | Sumitomo Pharmaceuticals Co., Ltd. | Therapeutic agent for cartilaginous diseases |
| IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| JP3927248B2 (en) * | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | HGF lyophilized formulation |
| AU7389496A (en) * | 1995-10-05 | 1997-04-28 | Genentech Inc. | Methods and compositions for treating vascular stenosis |
| US6146847A (en) * | 1996-11-01 | 2000-11-14 | Genespan Corporation | Stabilized transient gene expression |
| IL142557A0 (en) * | 1998-10-28 | 2002-03-10 | Snow Brand Milk Products Co Ltd | Remedies for bone metabolic errors |
| US7829072B2 (en) * | 2000-07-14 | 2010-11-09 | Carter Daniel C | Serum albumin compositions for use in cleansing or dermatological products for skin or hair |
| EP1270015A3 (en) * | 2001-06-29 | 2004-02-25 | Sankyo Company Limited | A complex comprising OCIF and Polysaccharide |
| SE525461C3 (en) | 2002-11-28 | 2005-03-23 | Prophymed Ab | New use of dextran sulfate |
| PL377731A1 (en) * | 2002-12-23 | 2006-02-06 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| JP4496086B2 (en) * | 2002-12-23 | 2010-07-07 | ブリストル−マイヤーズ スクイブ カンパニー | Increasing product quality using mammalian cell culture methods for protein production |
| US20070116768A1 (en) * | 2003-12-09 | 2007-05-24 | Michael Chorny | Sustained release preparations composed of biocompatible complex microparticles |
| SE538503C2 (en) | 2014-11-11 | 2016-08-16 | Tx Medic Ab | New dextran sulfate |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6045534A (en) * | 1983-08-22 | 1985-03-12 | Otsuka Pharmaceut Co Ltd | Hepatocyte growth factor |
| EP0412577A1 (en) * | 1986-05-09 | 1991-02-13 | Hoechst Aktiengesellschaft | Herbicidal agent |
| JP2564486B2 (en) * | 1986-07-14 | 1996-12-18 | 修治 橋本 | Hepatocyte growth factor |
| NZ226171A (en) * | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| JPH0240399A (en) * | 1988-07-27 | 1990-02-09 | Takeda Chem Ind Ltd | Complex or composition of fibroblast cell growth factor mutein |
| JPH0247916A (en) * | 1988-08-08 | 1990-02-16 | Nec Corp | Analog comparator |
| US5013714A (en) * | 1988-12-15 | 1991-05-07 | Lindstrom Richard L | Viscoelastic solution |
| US5486599A (en) * | 1989-03-29 | 1996-01-23 | The Board Of Trustees Of The Leland Stanford Junior University | Construction and use of synthetic constructs encoding syndecan |
| CA2022752C (en) * | 1989-08-11 | 1998-07-07 | Naomi Kitamura | Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor |
| JP2784455B2 (en) * | 1990-05-09 | 1998-08-06 | 敏一 中村 | Liver cirrhosis treatment |
| TW318142B (en) * | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd |
-
1992
- 1992-05-29 TW TW081104221A patent/TW318142B/zh active
- 1992-06-02 CA CA002070263A patent/CA2070263A1/en not_active Abandoned
- 1992-06-02 KR KR1019920009515A patent/KR100210698B1/en not_active IP Right Cessation
- 1992-06-03 HU HU9201856A patent/HUT62315A/en unknown
- 1992-06-03 EP EP92109374A patent/EP0517182B1/en not_active Expired - Lifetime
- 1992-06-03 ES ES92109374T patent/ES2094848T3/en not_active Expired - Lifetime
- 1992-06-03 DE DE69214355T patent/DE69214355T2/en not_active Expired - Fee Related
- 1992-06-03 AT AT92109374T patent/ATE143810T1/en not_active IP Right Cessation
-
1994
- 1994-08-19 US US08/292,051 patent/US5545722A/en not_active Expired - Lifetime
-
1996
- 1996-05-07 US US08/646,145 patent/US5736506A/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464815A (en) * | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
| US5849689A (en) * | 1993-09-08 | 1998-12-15 | Genentech, Inc. | Method of extending the plasma half-life of deletion variants of hepatocyte growth factor |
| US5851989A (en) * | 1993-09-08 | 1998-12-22 | Genentech, Inc. | Method of extending the plasma half-life of vascular endothelial cell growth factor |
Also Published As
| Publication number | Publication date |
|---|---|
| KR930000120A (en) | 1993-01-15 |
| DE69214355T2 (en) | 1997-03-06 |
| DE69214355D1 (en) | 1996-11-14 |
| EP0517182B1 (en) | 1996-10-09 |
| ES2094848T3 (en) | 1997-02-01 |
| US5545722A (en) | 1996-08-13 |
| ATE143810T1 (en) | 1996-10-15 |
| US5736506A (en) | 1998-04-07 |
| EP0517182A1 (en) | 1992-12-09 |
| HU9201856D0 (en) | 1992-08-28 |
| TW318142B (en) | 1997-10-21 |
| KR100210698B1 (en) | 1999-07-15 |
| HUT62315A (en) | 1993-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2070263A1 (en) | Hepatocyte-growth agent | |
| Harker et al. | Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates | |
| Harker et al. | Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates | |
| EP0260918B1 (en) | Megakaryocyte stimulatory factor | |
| Addonizio Jr et al. | Preservation of human platelets with prostaglandin E1 during in vitro simulation of cardiopulmonary bypass. | |
| Benigni et al. | Increased renal endothelin production in rats with reduced renal mass | |
| US6962903B2 (en) | Modified annexin proteins and methods for preventing thrombosis | |
| CA2585640C (en) | Use of 2-o desulfated heparin for the treatment of heparin-induced thrombocytopenia (hit) syndrome | |
| EP0341006B1 (en) | Smooth muscle cell growth inhibitor | |
| US5571686A (en) | Method of using megapoietin for prolonging the survival & viability of platlets | |
| US5707832A (en) | Process for the preparation of human factor VIII and analogs of factor VIII | |
| CA2361612A1 (en) | Peptides modulating activities of heparin, other glycosaminoglycans or proteoglycans | |
| Lowe-Krentz et al. | Multiple heparan sulfate proteoglycans synthesized by a basement membrane-producing murine embryonal carcinoma cell line | |
| JP3305355B2 (en) | Hepatocyte proliferation agent | |
| EP0979097A1 (en) | Hgf for treating acute renal failure | |
| US5155211A (en) | Megakaryocyte stimulatory factor | |
| Ponzin et al. | Characterization of macrophages elicited by intraperitoneal injection of hyaluronate | |
| EP0408146A2 (en) | Method for the purification of therapeutically active recombinant acidic fibroblast growth factor | |
| Shanberge et al. | Interrelationship of protamine and platelet factor 4 in the neutralization of heparin | |
| Castor et al. | Connective tissue activation. XXXVI. The origin, variety, distribution, and biologic fate of connective tissue activating peptide–III isoforms: characteristics in patients with rheumatic, renal, and arterial disease | |
| Jensen et al. | Early attachment of platelets, leukocytes, and fibrinogen in endothelial cell seeded Dacron grafts | |
| EP0061140B1 (en) | Chemorecruitins of leukocytes and inflamed tissues: a new class of natural leukopoietin proteins for chemorecruitment of specific leukocyte types from the bone marrow into blood circulation (leukocytosis and leftward shift reactions), process for their biotechnical preparation and pharmaceutical compositions | |
| Schneider | Fibrin-specific lysis of microthrombosis in endotoxemic rats by saruplase | |
| Im et al. | Developmental changes in insulin receptors of pig red blood cells | |
| Prosdocimi et al. | Clearance and in vivo release by heparin of human platelet factor 4 (PF4) in the rabbit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |